Karmanos Cancer Institute First in the World to use FDA-approved Radiofrequency Electromagnetic Device to Treat Liver Cancer
On Dec. 18, 2024, the Barbara Ann Karmanos Cancer Institute announced that the new TheraBionic P1 device, an…
AI-Based Tool Offers Exciting Advancement in Pancreatic Cancer Diagnostics
On Dec. 12, 2024, a study co-lead by researchers from the University of British Columbia, Vancouver General Hospital…
New Imaging Technique Accurately Detected Aggressive Kidney Cancer
On Oct. 29, 2024, a study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center (UCLA…
Biotechnology | Diagnostics | Disease | Genomics | NIH | Oncology | Therapeutics
Analysis identified 50 new genomic regions associated with kidney cancer risk
On Apr. 26, 2024, an international team of researchers led by the National Cancer Institute (NCI) released an…
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics
U.S. Preventive Services Task Force issued recommendation on screening for skin cancer
On Apr. 18, 2023, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening…
FDA approved first gene therapy for treatment of high-risk, non-muscle-invasive bladder cancer
On Dec. 16, 2022, the U.S. Food and Drug Administration approved Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences Announced Publication of Peer-Reviewed Journal Article Highlighting Ovarian Cancer Vaccine Technology
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
Biotechnology | FDA | Neurology | Oncology | Therapeutics
FDA approved Merck’s hypoxia-inducible factor-2 alpha inhibitor WELIREG (belzutifan)
On Aug. 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved WELIREG, an…
FDA approved first immunotherapy for initial treatment of gastric cancer
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
NIH scientists developed blood test to help improve liver cancer screening
On Jun. 11, 2020, scientists announced the development of a new test that can help identify people who…
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo (nivolumab) was approved by the FDA for the treatment…
UArizona Cancer Center received $69M grant forsSkin cancer prevention study
On Mar. 19, 2020, The UArizona Cancer Center announced it was awarded a five-year, $6.9 million prestigious Program…
Biotechnology | Disease | FDA | Oncology | Therapeutics
FDA approved first biosimilar for the treatment of certain breast and stomach cancers
On Dec. 1, 2017, the U.S. Food and Drug Administration (FDA) approved Mylan’s Ogivri (trastuzumab-dkst) as a biosimilar…
Siteman Cancer Center received a $10.4 million grant from the NCI
On Aug. 15, 2016, Siteman Cancer Center received a $10.4 million five-year grant to Washington University researchers and…
Researchers unlock genetic code of cancer-causing liver fluke parasite
On Sept. 10, 2014, an international team of scientists from Singapore, Thailand, China and Australia announced that they…
Biotechnology | Chemical | FDA | Oncology | Therapeutics | Women's Health
FDA approved Genentech’s Avastin plus chemotherapy for treatment of advanced cervical cancer
On Aug. 14. 2014, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Avastin (bevacizumab)…
Biotechnology | FDA | Oncology | Therapeutics
The U.S. FDA approved Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma
On Jan. 30, 2012, the U.S. Food and Drug Administration (FDA) approved Genentech’s Erivedge (vismodegib) capsule, the first…
FDA approved Cervarix, GlaxoSmithKline’s cervical cancer vaccine
On Oct. 16, 2009, GlaxoSmithKline announced the U.S. Food and Drug Administration (FDA) had approved Cervarix [Human papillomavirus…
Winship Cancer Institute received a 5-year, $12.5 million SPORE grant in head and neck cancer
On Sept. 10, 2007, the National Cancer Institute (NCI) awarded a five-year, $12.5 million Specialized Program of Research…
Yale Cancer Center was awarded a SPORE (Specialized Programs of Research Excellence) grant for translational research
On Oct. 10, 2006, Yale Cancer Center was awarded a SPORE (Specialized Programs of Research Excellence) grant for…
NCI researchers reported that the molecularly targeted drug bevacizumab slowed tumor growth in patients with metastatic renal cell carcinoma
On May 19, 2002, researchers from the National Cancer Institute reported that the molecularly targeted drug bevacizumab slowed…
Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer prevention
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
Stanford researchers discovered that mutations in a single gene are responsible for most common form of skin cancer
In 1996, Stanford Medicine developmental biologist Matthew Scott and a team at University of California, San Francisco discovered…
Cancer mortality rates declined nearly 3% between 1991 and 1995
In 1996, the American Cancer Society reported that the overall age-adjusted cancer mortality rate declined in each succeeding…
BRCA2 gene mapped to chromosome 13q12-13
In 1995, The BRCA2 gene was mapped to chromosomal 13q. Just fifteen months later, Wooster et al. reported…
Post-operative (adjuvant) radiation therapy and chemotherapy are found to improve survival in rectal cancer
On Mar. 4, 1991, researchers reported that post-operative (adjuvant) radiation therapy and chemotherapy were found to improve survival…
Results from the first chemoprevention trial to show efficacy (vitamin A analogue against mouth and throat tumors) were reported
On Sept. 20, 1990, results from the first chemoprevention trial to show efficacy (vitamin A analogue against mouth…
Bristol-Myers’ PARAPLATIN (carboplatin) was approved for the treatment of recurrent ovarian cancer
On Mar. 3, 1989, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers’ PARAPLATIN (carboplatin) for the treatment…
Biology | Diagnostics | Disease | Life Science History | Non-Profit Research | Oncology | Therapeutics
FDA approved Cisplatin, a platinum-containing anticancer compound
On Dec. 19, 1978, the U.S. Food and Drug Administration approved Cisplatin for use in testicular and ovarian…
Biotechnology | Diagnostics | Disease | Forestry | Non-Profit Research | Oncology | Therapeutics | Women's Health
Albert Einstein Cancer Center researchers identified the mechanism of action of Taxol
In 1976, Albert Einstein Cancer Center researchers identified the mechanism of action of Taxol, one of the most…